Top Page
Oxford BioMedica
(OTC:OXB)
Oxford BioMedica (OXB) vs. iShares MSCI United Kingdom ETF (EWC)
Oxford BioMedica Business Overview & Revenue Model
Oxford BioMedica Earnings Call Summary
Oxford BioMedica Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 151.21M | 128.80M | 89.54M | 139.99M | 142.80M | 87.73M |
| Gross Profit | 66.38M | 53.02M | 39.73M | 69.18M | 82.64M | 46.07M |
| EBITDA | -1.07M | -14.33M | -148.62M | -10.80M | 33.22M | 3.92M |
| Net Income | -37.06M | -43.19M | -157.49M | -39.16M | 19.01M | -6.25M |
Balance Sheet | ||||||
| Total Assets | 216.32M | 231.64M | 252.34M | 460.18M | 237.23M | 183.93M |
| Cash, Cash Equivalents and Short-Term Investments | 53.88M | 60.65M | 103.72M | 141.31M | 109.02M | 46.98M |
| Total Debt | 105.42M | 108.76M | 111.46M | 114.28M | 9.34M | 13.85M |
| Total Liabilities | 183.59M | 171.16M | 174.51M | 223.99M | 49.89M | 71.18M |
| Stockholders Equity | 32.73M | 57.05M | 74.01M | 204.65M | 187.34M | 112.75M |
Cash Flow | ||||||
| Free Cash Flow | -13.69M | -58.12M | -38.35M | -28.91M | 15.99M | -10.24M |
| Operating Cash Flow | -9.50M | -50.63M | -28.52M | -12.62M | 25.45M | 3.12M |
| Investing Cash Flow | -4.63M | 5.63M | 2.81M | -56.46M | -9.46M | -10.80M |
| Financing Cash Flow | -12.63M | 2.91M | -12.70M | 98.62M | 46.21M | 38.19M |
Oxford BioMedica Technical Analysis
Oxford BioMedica Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | £333.75M | ― | ― | ― | ― | ― | |
54 Neutral | £292.44M | 8.47 | 15.04% | ― | 1231.50% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £1.32B | -9.02 | -26.01% | ― | 22.03% | 20.01% | |
46 Neutral | £102.22M | -7.46 | ― | ― | ― | -94.12% | |
45 Neutral | £713.34M | ― | -74.64% | ― | 55.44% | 75.77% | |
39 Underperform | £121.56M | -7.90 | -209.34% | ― | 198.49% | -26.66% |
Oxford BioMedica Corporate Events
Oxford Biomedica PLC announced its total voting rights, with an issued share capital of 120,497,010 ordinary shares as of October 31, 2025. This figure is crucial for shareholders to determine their notification requirements under FCA rules, reflecting the company’s transparency and regulatory compliance.
The most recent analyst rating on (GB:OXB) stock is a Hold with a £667.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica PLC announced that its issued share capital consists of 120,497,010 ordinary shares, with no shares held in treasury, as of October 31, 2025. This figure represents the total number of voting rights in the company and is significant for shareholders to determine their notification requirements under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:OXB) stock is a Hold with a £667.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica (OXB) has been recognized as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership Awards Europe. This accolade highlights OXB’s excellence in quality, innovation, and service, underscoring its strong commercial momentum and growing demand for its CDMO services. The recognition reflects client trust and satisfaction, reinforcing OXB’s commitment to supporting the development of transformative therapies globally.
The most recent analyst rating on (GB:OXB) stock is a Hold with a £563.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford BioMedica announced its participation in upcoming investor conferences and events, highlighting its engagement with the investment community. The company’s senior management, including CEO Dr. Frank Mathias, will be involved in key presentations at the Stifel Healthcare Conference in New York and the Jefferies Global Healthcare Conference in London. This participation underscores OXB’s proactive approach to investor relations and its commitment to maintaining transparency and communication with stakeholders.
The most recent analyst rating on (GB:OXB) stock is a Hold with a £563.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica announced that its Chief Innovation Officer, Kyriacos Mitrophanous, exercised 26,210 LTIP options and sold the same number of shares at an average price of £5.758376 per share. This transaction, conducted on the London Stock Exchange, reflects ongoing managerial activities and may have implications for stakeholders monitoring insider transactions.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £970.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica announced that Dr. Heather Preston, a Non-Executive Director, has purchased 6,175 ordinary shares in the company. This transaction, conducted on the London Stock Exchange, highlights insider confidence in the company’s market position and future prospects. The purchase may positively influence stakeholder perceptions, reinforcing trust in the company’s strategic direction.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £970.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica announced the departure of Robert Ghenchev from its Board of Directors following his exit from Novo Holdings US. This change comes as the company continues to strengthen its position as a leading cell and gene therapy CDMO. Novo Holdings A/S, a major shareholder, retains the right to nominate a new director, subject to board approval, indicating ongoing strategic alignment and potential future developments.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £970.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica announced that Natalie Walter, Group General Counsel and Company Secretary, exercised 28,321 LTIP options and 39,679 DBP options, subsequently selling 68,000 shares at an average price of £6.116876 per share. This transaction, conducted on the London Stock Exchange, reflects the company’s adherence to EU Market Abuse Regulation requirements and highlights the ongoing financial activities of its senior management.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £970.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford BioMedica (OXB) has expanded its US presence by acquiring a commercial-scale viral vector manufacturing facility in North Carolina from Resilience. This acquisition aligns with OXB’s strategy to enhance its US GMP capacity, meeting growing client demand and strengthening its global CDMO network. The facility will support late-stage programs and commercial launches, particularly in the adeno-associated virus field, and is expected to bolster OXB’s competitive position in the global viral vector market. The acquisition is anticipated to support OXB’s long-term growth outlook and maintain existing financial guidance, with integration planning already underway.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £970.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica, a leading cell and gene therapy contract development and manufacturing organization (CDMO), specializes in viral vector manufacturing and collaborates with pharmaceutical and biotechnology companies worldwide.
Oxford BioMedica reported strong financial results for the first half of 2025, with a 44% increase in revenues to £73.2 million, driven by high demand for its CDMO services. The company has improved its profitability significantly, reducing its operating EBITDA loss and strengthening its balance sheet with new financial facilities and share placements. The company’s strategic initiatives, including expanding its US commercial-scale GMP capacity, are set to support its growth trajectory and enhance its market position.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £6.87 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica PLC announced that its issued share capital as of August 31, 2025, consists of 120,182,204 ordinary shares, with no shares held in treasury. This figure represents the total number of voting rights in the company and is relevant for shareholders determining their interest in OXB under the FCA’s rules. This announcement reflects OXB’s transparency in its operations and could impact shareholder decisions regarding their stakes in the company.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £930.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.